edrophonium has been researched along with Disease Exacerbation in 4 studies
Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We review six patients who presented with only DHS, responded to intravenous edrophonium and turned out to have myasthenia gravis (MG) including similar patients who were previously documented." | 7.79 | Dropped head with positive intravenous edrophonium, progressing to myasthenia gravis. ( Eura, N; Kataoka, H; Sawa, N; Ueno, S, 2013) |
| " We review six patients who presented with only DHS, responded to intravenous edrophonium and turned out to have myasthenia gravis (MG) including similar patients who were previously documented." | 3.79 | Dropped head with positive intravenous edrophonium, progressing to myasthenia gravis. ( Eura, N; Kataoka, H; Sawa, N; Ueno, S, 2013) |
| "To assess the effect of oral corticosteroid therapy on the frequency of development of generalized myasthenia gravis within 2 years, the incidence of thymoma, and the amount of edrophonium needed for a positive test result in patients with ocular myasthenia gravis." | 3.72 | Development of generalized disease at 2 years in patients with ocular myasthenia gravis. ( Homel, P; Kupersmith, MJ; Latkany, R, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sawa, N | 1 |
| Kataoka, H | 1 |
| Eura, N | 1 |
| Ueno, S | 1 |
| Kupersmith, MJ | 1 |
| Latkany, R | 1 |
| Homel, P | 1 |
| Guillermo, GR | 1 |
| Téllez-Zenteno, JF | 1 |
| Weder-Cisneros, N | 1 |
| Mimenza, A | 1 |
| Estañol, B | 1 |
| Remes-Troche, JM | 1 |
| Cantu-Brito, C | 1 |
| Hatanaka, Y | 1 |
| Hemmi, S | 1 |
| Morgan, MB | 1 |
| Scheufele, ML | 1 |
| Claussen, GC | 1 |
| Wolfe, GI | 1 |
| Oh, SJ | 1 |
4 other studies available for edrophonium and Disease Exacerbation
| Article | Year |
|---|---|
Dropped head with positive intravenous edrophonium, progressing to myasthenia gravis.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Disease Progression; Edrophonium; Female; Head; | 2013 |
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodi | 2003 |
Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients.
Topics: Adult; Autoantibodies; Disease Progression; Edrophonium; Electromyography; Female; Follow-Up Studies | 2004 |
Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG.
Topics: Adult; Autoantibodies; Causality; Cholinesterase Inhibitors; Disease Progression; Drug Resistance; E | 2005 |